| Including all voices in international data-sharing governance J Kaye, SF Terry, E Juengst, S Coy, JR Harris, D Chalmers, ES Dove, ... Human Genomics 12, 1-6, 2018 | 66 | 2018 |
| Promissory futures and possible pasts: the dynamics of contemporary expectations in regenerative medicine M Morrison BioSocieties 7, 3-22, 2012 | 63 | 2012 |
| StemBANCC: governing access to material and data in a large stem cell research consortium M Morrison, C Klein, N Clemann, DA Collier, J Hardy, B Heiβerer, ... Stem Cell Reviews and Reports 11, 681-687, 2015 | 62 | 2015 |
| Towards ‘Engagement 2.0’: Insights from a study of dynamic consent with biobank participants HJA Teare, M Morrison, EA Whitley, J Kaye Digital Health 1, 2055207615605644, 2015 | 62 | 2015 |
| CRISPR in context: towards a socially responsible debate on embryo editing M Morrison, S de Saille Palgrave Communications 5 (1), 2019 | 58 | 2019 |
| The evolution of withdrawal: negotiating research relationships in biobanking K Melham, LB Moraia, C Mitchell, M Morrison, H Teare, J Kaye Life sciences, society and policy 10, 1-13, 2014 | 58 | 2014 |
| The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks M Morrison, J Bell, C George, S Harmon, M Munsie, J Kaye Regenerative medicine 12 (6), 693-703, 2017 | 51 | 2017 |
| Tensions in ethics and policy created by National Precision Medicine Programs J Minari, KB Brothers, M Morrison Human genomics 12, 1-10, 2018 | 47 | 2018 |
| Patenting foundational technologies: Lessons from CRISPR and other core biotechnologies O Feeney, J Cockbain, M Morrison, L Diependaele, K Van Assche, ... The American Journal of Bioethics 18 (12), 36-48, 2018 | 43 | 2018 |
| Exploring the role of dedicated online biotechnology news providers in the innovation economy M Morrison, L Cornips Science, technology, & human values 37 (3), 262-285, 2012 | 43 | 2012 |
| Patenting human pluripotent cells: balancing commercial, academic and ethical interests G Bahadur, M Morrison Human Reproduction 25 (1), 14-21, 2010 | 39 | 2010 |
| Genome editing: the dynamics of continuity, convergence, and change in the engineering of life P Martin, M Morrison, I Turkmendag, B Nerlich, A McMahon, S de Saille, ... New Genetics and Society 39 (2), 219-242, 2020 | 31 | 2020 |
| Growth hormone, enhancement and the pharmaceuticalisation of short stature M Morrison Social Science & Medicine 131, 305-312, 2015 | 30 | 2015 |
| Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic D Nicol, L Eckstein, M Morrison, JS Sherkow, M Otlowski, T Whitton, ... Genome medicine 9, 1-4, 2017 | 27 | 2017 |
| “A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science M Morrison Life sciences, society and policy 13 (1), 7, 2017 | 22 | 2017 |
| Reflection on the enactment and impact of safety laws for regenerative medicine in Japan K Takashima, M Morrison, J Minari Stem Cell Reports 16 (6), 1425-1434, 2021 | 20 | 2021 |
| Governance of research consortia: challenges of implementing Responsible Research and Innovation within Europe M Morrison, M Mourby, H Gowans, S Coy, J Kaye Life Sciences, Society and Policy 16, 1-19, 2020 | 20 | 2020 |
| Regulating human stem cell research and therapy in low-and middle-income countries: Malaysian perspectives MF Bin Abdul Aziz, M Morrison, J Kaye New Genetics and Society 37 (1), 2-20, 2018 | 20 | 2018 |
| Infrastructural expectations: exploring the promise of international large-scale induced pluripotent stem cell banks M Morrison New Genetics and Society 36 (1), 66-83, 2017 | 18 | 2017 |
| Gene therapy regulation: could in-body editing fall through the net? M Mourby, M Morrison European Journal of Human Genetics 28 (7), 979-981, 2020 | 15 | 2020 |
